Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIB-Q22
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Sciences
01
Overview
CIB-Q22: sourced facts only. name: "we designed and synthesized 55 derivatives, culminating in the identification of CIB-Q22, which exhibited potent PC inhibition (IC50 = 1.74 nM) and suppressed HCC cell viability (IC50 = 25.18 nM), comparable to erianin." [PMID:42286802]; target: "we designed and synthesized 55 derivatives, culminating in the identification of CIB-Q22, which exhibited potent PC inhibition (IC50 = 1.74 nM) and suppressed HCC cell viability (IC50 = 25.18 nM), comparable to erianin." [PMID:42286802]; developer: "National Engineering Research Center for Natural Medicines, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610213, China." [PMID:42286802]; stage: "In vivo, CIB-Q22 exhibited comparable antitumor efficacy but improved safety compared to sorafenib." [PMID:42286802]
02
Targets
PROC (Protein C)
Beyond the preview
Go deeper on CIB-Q22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIB-Q22.